Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
An open-label, non-randomized, monocenter, single-dose, phase I basic science trial to evaluate pharmacokinetics and safety of Murepavadin administered as single intravenous infusion to 32 adults with Renal function impairment
Primary outcome measures:
Measuring the plasma concentrations of Murepavadin
Conclusion:
Murepavadin was well tolerated in all dose groups. Renal function affects its elimination, and its impairment increases the plasma concentration of Murepavadin. Dose adjustment is needed for those with impaired renal function.
…